ORTX News and Press, Orchard Therapeutics plc From 12/11/23

BOSTON and LONDON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the Swiss Agency for Therapeutic Products (Swissmedic) has approved Libmeldy ® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, ...

2023-12-04 07:02:21 ET Summary Kyowa Kirin is acquiring Orchard Therapeutics for $16 per share and a CVR worth up to $1, adding up to a $350 million deal. The acquisition comes after extensive research collaboration and will allow Kyowa to accelerate research programs. The CVR...

2023-11-30 07:24:17 ET Orchard Therapeutics ( NASDAQ: ORTX ) announced on Thursday that its investigational hematopoietic stem cell (HSC) gene therapy has received Fast Track Designation from the U.S. Food and Drug Administration for the potential treatment of the Hurler subtype...

Previously reported results from ongoing proof-of-concept study showed extensive metabolic correction, continued cognitive, motor, and physical development, as well as early improvements in skeletal health Additionally, study investigators presented favorable outcomes for other disease ...

2023-11-21 08:46:55 ET More on Orchard Therapeutics Orchard Therapeutics: A Reassessment Biggest stock movers today: BlackBerry, Clorox, Rivian Automotive and more Kyowa Kirin to buy Orchard Therapeutics for $387M Seeking Alpha’s Quant Rating on Orchar...

2023-11-19 07:11:04 ET Summary Top merger stocks held by funds include Seagen and VMware, with pending deals expected to close soon. Market uncertainty surrounding the VMware merger has led to a perplexing stock price for its shares. Looking at the top holdings of arb hedge fu...

2023-11-13 07:20:59 ET More on Orchard Therapeutics Orchard Therapeutics: A Reassessment Biggest stock movers today: BlackBerry, Clorox, Rivian Automotive and more Kyowa Kirin to buy Orchard Therapeutics for $387M Seeking Alpha’s Quant Rating on Orchar...

Reported $5.6 million in quarterly Libmeldy net revenue and $12.7 million year-to-date Planned acquisition by Kyowa Kirin valued at up to $477.6 million with an anticipated closing in the first quarter of 2024 Biologics License Application for OTL-200 in MLD accepted by U.S. FDA...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Orchard Therapeutics plc (ORTX) is expected to report $-1.3 for Q3 2023